Movement Alert｜RemeGen Rises 4.23% in Regular Trading, A-Share Buyback Plan Enters Implementation Phase as Innovative Drug Sector Strengthens

Market Focus07-22 09:48

On July 22, RemeGen (09995.HK) rose 4.23% in regular trading, trading at HK$88.35/share, with turnover of HK$84.836 million.

On the news front, the company disclosed its pre-buyback shareholding structure on July 21, publishing the top ten A-share shareholders and their holdings as of July 17, providing baseline data for the imminent first centralized bidding buyback program. This marks the buyback entering the substantive operational stage. The board of directors had unanimously approved the plan on July 19, authorizing the repurchase of A-shares using no more than RMB 50 million for employee stock ownership plans or equity incentives.

Additionally, RemeGen's core product Telitacicept was recently included in the National Essential Drug Catalogue under the immunological agents category, further brightening its commercialization outlook. The broader innovative drug sector continues to strengthen, with peers AKESO up 7.08%, BEIGENE up 1.87%, and INNOVENT BIO up 1.74%, reflecting sustained capital inflows into the sector supported by policy tailwinds and active BD transactions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191396642?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 09:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191396642","market":"hk","top_or_hot":-1,"title":"Movement Alert｜RemeGen Rises 4.23% in Regular Trading, A-Share Buyback Plan Enters Implementation Phase as Innovative Drug Sector Strengthens","media":"Market Focus","content":"<p><p>On July 22, RemeGen (09995.HK) rose 4.23% in regular trading, trading at HK$88.35/share, with turnover of HK$84.836 million.</p><p>On the news front, the company disclosed its pre-buyback shareholding structure on July 21, publishing the top ten A-share shareholders and their holdings as of July 17, providing baseline data for the imminent first centralized bidding buyback program. This marks the buyback entering the substantive operational stage. The board of directors had unanimously approved the plan on July 19, authorizing the repurchase of A-shares using no more than RMB 50 million for employee stock ownership plans or equity incentives.</p><p>Additionally, RemeGen's core product Telitacicept was recently included in the National Essential Drug Catalogue under the immunological agents category, further brightening its commercialization outlook. The broader innovative drug sector continues to strengthen, with peers AKESO up 7.08%, BEIGENE up 1.87%, and INNOVENT BIO up 1.74%, reflecting sustained capital inflows into the sector supported by policy tailwinds and active BD transactions.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜RemeGen Rises 4.23% in Regular Trading, A-Share Buyback Plan Enters Implementation Phase as Innovative Drug Sector Strengthens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜RemeGen Rises 4.23% in Regular Trading, A-Share Buyback Plan Enters Implementation Phase as Innovative Drug Sector Strengthens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-22 09:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 22, RemeGen (09995.HK) rose 4.23% in regular trading, trading at HK$88.35/share, with turnover of HK$84.836 million.</p><p>On the news front, the company disclosed its pre-buyback shareholding structure on July 21, publishing the top ten A-share shareholders and their holdings as of July 17, providing baseline data for the imminent first centralized bidding buyback program. This marks the buyback entering the substantive operational stage. The board of directors had unanimously approved the plan on July 19, authorizing the repurchase of A-shares using no more than RMB 50 million for employee stock ownership plans or equity incentives.</p><p>Additionally, RemeGen's core product Telitacicept was recently included in the National Essential Drug Catalogue under the immunological agents category, further brightening its commercialization outlook. The broader innovative drug sector continues to strengthen, with peers AKESO up 7.08%, BEIGENE up 1.87%, and INNOVENT BIO up 1.74%, reflecting sustained capital inflows into the sector supported by policy tailwinds and active BD transactions.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1191396642","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191396642","pubTimestamp":1784684926,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 22, RemeGen (09995.HK) rose 4.23% in regular trading, trading at HK$88.35/share, with turnover of HK$84.836 million.On the news front, the company disclosed its pre-buyback shareholding...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"异动提醒|RemeGen常规交易涨4.23% 创新药板块走强A股回购计划进入实施阶段","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On July 22, RemeGen (09995.HK) rose 4.23% in regular trading, trading at HK$88.35/share, with turnover of HK$84.836 million.On the news front, the company disclosed its pre-buyback shareholding structure on July 21, publishing the top ten A-share shareholders and their holdings as of July 17, providing baseline data for the imminent first centralized bidding buyback program. This marks the buyback entering the substantive operational stage. The board of directors had unanimously approved the plan on July 19, authorizing the repurchase of A-shares using no more than RMB 50 million for employee stock ownership plans or equity incentives.Additionally, RemeGen's core product Telitacicept was recently included in the National Essential Drug Catalogue under the immunological agents category, further brightening its commercialization outlook. The broader innovative drug sector continues to strengthen, with peers AKESO up 7.08%, BEIGENE up 1.87%, and INNOVENT BIO up 1.74%, reflecting sustained capital inflows into the sector supported by policy tailwinds and active BD transactions.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191396642","isCrawlerRequest":true}